ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026
An Integrated DNA Nanoprobe for Intranuclear Imaging and In Situ Profiling of OGG1 Activity.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Accurate quantification of 8-oxoguanine DNA glycosylase-1 (OGG1) activity in the cell nucleus is crucial for evaluating the DNA oxidative damage marker 8-oxoguanine (8-oxoG). However, due to the difficulty in nuclear localization and the predicament of strong signal output, subcellular imaging has not yet been achieved. Herein, we report a nuclear-targeted DNA triangular prism nanoprobe (TP-SA) designed to overcome the aforementioned limitations via a dual-pronged strategy. TP-SA integrated an AS1411 aptamer for active nucleus delivery and a Förster resonance energy transfer (FRET) array for signal readout. In living cells, TP-SA enabled monitoring of nuclear OGG1 activity, revealing distinct variations in basal enzymatic levels across various cell lines. Additionally, preliminary evaluations in bronchoalveolar lavage fluid from pneumonia patients suggested its applicability in clinical settings. Furthermore, it served as a platform for pharmacological validation, effectively assessing the effects of small-molecule activators on OGG1. This study established a powerful framework for designing spatially specific nanoprobes, successfully enabling intranuclear imaging and in situ profiling of OGG1 activity. This advancement has transcended the boundaries of traditional biosensors, providing powerful and multi-dimensional tools for basic biological sensing, clinical analysis in complex biological fluids, and precision medicine fields.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.